DE69527986T2 - Antigene arznei zur behandlung oder vorbeugung - Google Patents

Antigene arznei zur behandlung oder vorbeugung

Info

Publication number
DE69527986T2
DE69527986T2 DE69527986T DE69527986T DE69527986T2 DE 69527986 T2 DE69527986 T2 DE 69527986T2 DE 69527986 T DE69527986 T DE 69527986T DE 69527986 T DE69527986 T DE 69527986T DE 69527986 T2 DE69527986 T2 DE 69527986T2
Authority
DE
Germany
Prior art keywords
lps
helicobacter
vaccine composition
preparation
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69527986T
Other languages
German (de)
English (en)
Other versions
DE69527986D1 (de
Inventor
George Barr
Jane Buck
Vincent Doidge
John Kleinig
Adrian Lee
Elizabeth Pietrzykowski
Alexander Quinn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Ltd
UNSW Sydney
Original Assignee
CSL Ltd
UNSW Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Ltd, UNSW Sydney filed Critical CSL Ltd
Publication of DE69527986D1 publication Critical patent/DE69527986D1/de
Application granted granted Critical
Publication of DE69527986T2 publication Critical patent/DE69527986T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/121—Helicobacter (G); Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DE69527986T 1994-02-21 1995-02-17 Antigene arznei zur behandlung oder vorbeugung Expired - Lifetime DE69527986T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPM3995A AUPM399594A0 (en) 1994-02-21 1994-02-21 Antigenic preparation for treatment or prevention of helicobacter infection
PCT/AU1995/000077 WO1995022563A1 (en) 1994-02-21 1995-02-17 Antigenic preparation for treatment or prevention of helicobacter infection

Publications (2)

Publication Number Publication Date
DE69527986D1 DE69527986D1 (de) 2002-10-02
DE69527986T2 true DE69527986T2 (de) 2003-04-10

Family

ID=3778612

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69527986T Expired - Lifetime DE69527986T2 (de) 1994-02-21 1995-02-17 Antigene arznei zur behandlung oder vorbeugung

Country Status (10)

Country Link
US (1) US6663873B2 (enExample)
EP (1) EP0804489B1 (enExample)
JP (1) JPH10500102A (enExample)
KR (1) KR100351534B1 (enExample)
AT (1) ATE222930T1 (enExample)
AU (2) AUPM399594A0 (enExample)
CA (1) CA2182274C (enExample)
DE (1) DE69527986T2 (enExample)
NZ (2) NZ281146A (enExample)
WO (1) WO1995022563A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM399594A0 (en) * 1994-02-21 1994-03-17 Csl Limited Antigenic preparation for treatment or prevention of helicobacter infection
BR9509275A (pt) * 1994-10-05 1997-12-23 Antex Biolog Inc Processos para produzir bactéria helicobacter tendo propriedades antigênicas aumentadas testar um agente antimicrobiano potencial detectar anticorpos de um hospedeiro para bactéria helicobacter e bactéria helicobacter em um animal ou amostra biológica deste produzir anticorpos antibacterianos e estimular e estimular uma imunoresposta em um animal bactéria helicobacter vacina e estojo de teste diagnóstico para detectar um hospedeiro de anticorpos para bactéria helicobacter ou para detectar bactéria helicobacter
US5679564A (en) * 1994-10-05 1997-10-21 Antex Biologics, Inc. Methods for producing enhanced antigenic campylobacter bacteria and vaccines
AU693679B2 (en) * 1995-04-21 1998-07-02 Csl Limited Protective helicobacter antigens
WO1996033220A1 (en) * 1995-04-21 1996-10-24 Csl Limited Protective helicobacter antigens
WO1998042189A1 (en) * 1997-03-26 1998-10-01 Avant Immunotherapeutics, Inc. POLYPEPTIDES WHICH IMMUNOREACT WITH POLYCLONAL ANTISERA AGAINST $i(H. PYLORI)
GB9715702D0 (en) * 1997-07-24 1997-10-01 Univ Bristol Bacterial isolate
US6599509B2 (en) * 1997-09-02 2003-07-29 Massachusetts Institute Of Technology Compositions and methods comprising helicobacter antigens for treatment and prevention of inflammatory bowel disease
WO2002066631A1 (en) * 2001-02-21 2002-08-29 Denka Seiken Co., Ltd. Antibodies recognizing helicobacter pylori and method of detecting helicobacter pylori
DE102004024674A1 (de) * 2004-05-18 2005-12-15 Wolfgang Lorenz Mittel und Verfahren zur Diagnose, Prophylaxe und Therapie von Bindegewebserkrankungen
EP1930025B1 (en) 2005-08-05 2013-05-01 The University of Tokushima ANTIGEN-AND-DRUG VEHICLE WHICH ENABLES THE CHANGEOVER FROM THE SELECTIVE PRODUCTION OF IgA ANTIBODY TO THE PRODUCTION OF BOTH OF IgA AND IgG ANTIBODIES, AND TRANSNASAL/TRANSMUCOSAL VACCINE USING THE VEHICLE
HUE038915T2 (hu) 2013-01-17 2018-12-28 Arsanis Biosciences Gmbh MDR E. colira fajlagos antitest
KR102301188B1 (ko) 2014-02-06 2021-09-13 엑스4 파마슈티컬스 (오스트리아) 게엠베하 이. 콜라이 특이성 항체 서열
NZ723328A (en) 2014-02-24 2018-01-26 Glycovaxyn Ag Compositions comprising e. coli o25b antigen, uses thereof and methods of manufacture
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
IL286467B2 (en) 2019-03-18 2026-02-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
CR20210522A (es) 2019-03-18 2021-12-17 Janssen Pharmaceuticals Inc Bioconjugados de antígenos–polisacáridos de e. coli, métodos de producción y métodos de utilización de los mismos
CN111467368B (zh) * 2020-04-13 2021-05-28 江南大学 含庚糖链的寡糖化合物在制备幽门螺旋杆菌疫苗中的应用
PE20231385A1 (es) 2020-09-17 2023-09-12 Janssen Pharmaceuticals Inc Composiciones de vacunas multivalentes y usos de las mismas

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU644121B2 (en) 1989-12-04 1993-12-02 Auspharm International Limited Rapid in vitro test for helicobacter pylori using saliva
US5217872A (en) * 1990-02-27 1993-06-08 The United States Of America As Represented By The Department Of Health And Human Services Method for detection of borrelia burgdorferi antigens
US5098755A (en) * 1990-11-21 1992-03-24 Tanquary Albert C Textured thermoplastic elastomeric film, articles comprising same, and method of making such textured thermoplastic elastomeric film and articles
MX9301706A (es) 1992-04-13 1994-05-31 Oravax Inc Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
US5580563A (en) * 1992-05-01 1996-12-03 Tam; James P. Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof
US6258359B1 (en) * 1993-05-19 2001-07-10 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
US6406703B1 (en) * 1993-07-27 2002-06-18 Csl Limited Treatment of H. pylori associated gastroduodenal disease
EP0716613B1 (en) * 1993-07-27 2003-07-09 Csl Limited Treatment of helicobacter associated gastroduodenal disease
US5840302A (en) * 1993-11-10 1998-11-24 Bristol-Myers Squibb Company Treatment of bacterially-induced inflammatory diseases
AUPM399594A0 (en) * 1994-02-21 1994-03-17 Csl Limited Antigenic preparation for treatment or prevention of helicobacter infection
AUPM612494A0 (en) * 1994-06-08 1994-06-30 Csl Limited Treatment or prevention of helicobacter infection
US5679564A (en) * 1994-10-05 1997-10-21 Antex Biologics, Inc. Methods for producing enhanced antigenic campylobacter bacteria and vaccines
WO1996033220A1 (en) * 1995-04-21 1996-10-24 Csl Limited Protective helicobacter antigens
US5997881A (en) * 1995-11-22 1999-12-07 University Of Maryland, Baltimore Method of making non-pyrogenic lipopolysaccharide or A
AU3458299A (en) * 1998-03-31 1999-10-18 United States Of America, As Represented By The Secretary Of Agriculture, The Monoclonal antibodies against (campylobacter jejuni) and (campylobacter coli) outer membrane antigens
AU770498B2 (en) * 1998-06-19 2004-02-26 Merieux Oravax LT and CT in parenteral immunization methods against helicobacter infection

Also Published As

Publication number Publication date
CA2182274A1 (en) 1995-08-24
NZ329879A (en) 1999-10-28
KR970701209A (ko) 1997-03-17
KR100351534B1 (ko) 2003-03-15
NZ281146A (en) 1998-04-27
WO1995022563A1 (en) 1995-08-24
AU1801195A (en) 1995-09-04
EP0804489A1 (en) 1997-11-05
AU693864B2 (en) 1998-07-09
EP0804489A4 (enExample) 1997-11-19
DE69527986D1 (de) 2002-10-02
US20020122794A1 (en) 2002-09-05
EP0804489B1 (en) 2002-08-28
AUPM399594A0 (en) 1994-03-17
JPH10500102A (ja) 1998-01-06
CA2182274C (en) 2007-05-22
US6663873B2 (en) 2003-12-16
ATE222930T1 (de) 2002-09-15
HK1004677A1 (en) 1998-12-04

Similar Documents

Publication Publication Date Title
DE69534992T2 (de) Mutierendes enterotoxin als nichttoxisches orales adjuvans
DE69533673T2 (de) Behandlung und prävention von helicobacter-infektionen
US5538729A (en) Oral treatment of helicobacter infection
DE60030274T2 (de) Aus ganzen zellen bestehender impfstoff, der staphylococcus aureus antigen enthält
US6663873B2 (en) Antigenic preparation for treatment or prevention of helicobacter infection
DE69822919T2 (de) Spezifische Antikörper zur Verwendung in der Herstellung pharmazeutischer Zusammensetzungen nützlich für die Vorbeugung oder Behandlung von Gastritis, Magen- und Zwölffingerdarmgeschwüren
DE69708318T2 (de) Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
DE69432929T2 (de) Behandlung eines durch helicobakter verursachten gastroduodenalen krankheit
EP0220387B1 (de) Konjugatimpfstoffe gegen Infektionen durch gramnegative Bakterien, Verfahren zu deren Herstellung sowie Verwendung derselben
DE2736223A1 (de) Allergen enthaltende substanzen, verfahren zu ihrer herstellung und ihre verwendung
DE69231663T2 (de) Polysaccharid-protein-konjugate
DE69330464T2 (de) Gruppe b streptococcus typ ii und typ v polysaccharid-protein konjugate als impfstoffe
DE3882781T3 (de) Impfstoff gegen Pasteurella.
DE69226944T2 (de) Darstellung und verwendung von mit formalin abgetöteten e. coli bakterien, die das kolonie-faktor-antigen (cfa) expremieren zur impfung gegen das die darminfektion/diarrhoe in menschen auslösende darmbakterium e. coli
US6153191A (en) Giardia treatment and antibody
DE69131525T2 (de) Pasteurella multocida toxoid enthaltende impfstoffe
DE3685700T2 (de) E87ag-antigen des pseudomonas aeruginosa, monoklonale antikoerper dagegen und hybridom.
DE3541044A1 (de) Neues, allgemein anwendbares antigen (psc-a) gegen pseudomonas aeruginosa, das als mittel zum schutz gegen pseudomonas aeruginosa-infektion wirkt
DE69534635T2 (de) Verfahren zur produktion von verstärkt antigen wirkenden heliobacter sp. und vakzine die diesen enthalten
US7217541B2 (en) Method of making CS6 antigen vaccine for treating, preventing, or inhibiting enterotoxigenic Escherichia coli infections
DE69121999T2 (de) Verfahren und Produkt für die Behandlung von Magenkrankheiten
DE3750549T2 (de) Impfstoff gegen schweinedysenterie.
HK1004677B (en) Antigenic preparation for treatment or prevention of helicobacter infection
US6036961A (en) Intestinal protozoal vaccines
AU675938C (en) Oral treatment of helicobacter infection